Colorectal
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Clinical takeawayConsider using the T/S ratio (tumor area/SUVmax) from pretreatment MRI/PET-CT to stratify risk and guide individualized neoadjuvant strategies in locally advanced rectal cancer.
What it foundPatients with a high T/S ratio (cut-off 55.81) had significantly poorer 3-year relapse-free survival (51.8% vs. 84.0%, p = 0.002).
ContextThis study introduces a novel imaging biomarker that refines risk stratification in locally advanced rectal cancer, addressing a gap in pretreatment prognostic tools.
Emergingsuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017
Decision at stakepredicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.
Shioi I … Saeki H · Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland · IF 3.2 · PubMed ↗